Mr. Leung has over 15 years’ experience in the life science and finance industries. Currently, he is the Chairman of Great Bay Bio and also serves as Director in both Uni-bio Science Group and DotBio.  He has broad experience in sourcing, evaluating and executing new growth opportunities, supporting the execution and alliance management of 8 deals, including the in-licensing of next generation oncology, inflammation and respiratory drugs from MNCs. 

Mr. Leung also has extensive experience in the finance industry where he worked in healthcare investment banking in Merrill Lynch and a family office, helping evaluated IPO opportunities for multiple companies across the US and PRC. Up to date, Mr. Leung has led and successfully raised over USD 60M across multiple of his ventures. Mr. Leung was awarded the prestigious honour of World Outstanding Young Leaders Award from Yazhou Zhoukan in 2016, Entrepreneur of the Year from CAPITAL in 2017, Young Industrialist Awards of Hong Kong in 2020, and Gen.T Social Impact and Leader of Tomorrow 2021.
Mr. Leung is currently a Chartered Financial Analyst and a member of The Hong Kong Society of Financial Analysts. He was also elected the Vice Chairman of Pharmaceutical & Chemical group of the Federation of Hong Kong Industries (FHKI). Mr. Leung holds a BSc in Biochemistry from Imperial College London, an MSc in Pharmacology from the University of Oxford, and EMBA from Tsinghua-INSEAD. In addition, he holds a Professional Diploma in Corporate Governance & Directorship from the HongKong Institute of Directors.

Dr. Michael Chen is the CEO & Co-founder of Great Bay Bio. He has more than 30 years of experience in technologies, operation management, and business partnership in the biopharmaceutical industry. Prior to Great Bay Bio, Dr. Chen served as the senior positions in Synageva, Faville, and Applied Biotech. In the last five years Dr. Chen has led the GBB team to successfully launch several AI-enabled bioprocessing platforms.
Dr. Chen holds a Ph.D. degree in biochemistry from the University of Georgia and a postdoctoral position from The Scripps Research Institute in San Diego. He has received several NIH postdoctoral scholarships and has published 14 SCI papers, and owns more than 50 patents.

George Li is a Managing Partner with Proxima Ventures. George has over 15 years’ experience of founding, investing and building life science start-up companies and has accumulated hands-on experience of advising and investing early stage medtech companies, specially in interdisciplinary innovations. George led Proxima Ventures investment of  Vickor, Nanoablation, Matridx, Mobidrop, Wisdom Health and serve as boarddirector of those companies.

Prior to joining Proxima Ventures，George founded Biohub which is a leading medical incubator & accelerator in China and has built a leading medical ecosystem which has offices in Wuhan, Suzhou, Zhengzhou, Chongqing and Chengdu to provide wet lab and cGMP facilities and provides access to top hospitals and KOLs in China. Biohub has incubated and supported 100+ early stage life science companies covering biotech, medical devices, diagnostic and medical services.

Prior to Biohub, George was co-founder of Biohermsand grew it into a leading IVD company in China.

George also serves as the Chair judge for Chunhui business plan contest and mentor early stage companies.

George holds a MBA from Hult International Business School and a Bachelor degree from Zhejiang University.

Mr. Jack Wang is currently partner of Tiger Jade Capital where he sits in investment committee and is also responsible for overall investor relationship. From June 2017 to January, 2022, Mr. Wang served as a Managing Director at CMB International Asset Management Limited (“CMBI”), where he led the firm’s effort in various notable investments including Tencent Music Entertainment Group, Xiaomi Corporation, and Grab Holdings Inc., etc and worked closely with the firm’s healthcare team and participated in project fund investing in leading healthcare companies in China, such as Burning Rock Biotech Limited and Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Prior to joining CMBI, Mr. Wang worked at CSOP Asset Management Limited from April 2012 to August 2016 with his last position being the Deputy Chief Marketing Officer, where he was instrumental in building the firm to become the largest RMB QFII player in the market. Mr. Wang also worked at Deutsche Securities Asia and Goldman Sachs (Asia) L.L.C. from November 2006 to March 2012.

Dr. Ting Xie from Hillhouse BioVenture, focuses onthe investment of cutting edge life science technologies and new therapies globally, he serves as a Board Member at various biotech companies including Elpiscience. Prior to that he worked for a Healthcare specialized Private Equity fund HCR in New York metro area and a Wall Street financial institution Alliance Bernstein covering Biotech and Spec Pharma. He obtained a Ph.D. degreefrom Harvard University, and BS degree from Tsinghua University.